Intech Investment Management LLC Grows Stock Position in United Therapeutics Corporation $UTHR

Intech Investment Management LLC grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 20.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,523 shares of the biotechnology company’s stock after purchasing an additional 4,020 shares during the quarter. Intech Investment Management LLC’s holdings in United Therapeutics were worth $11,462,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Clearstead Advisors LLC increased its position in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares in the last quarter. Independent Advisor Alliance grew its stake in shares of United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the period. Bessemer Group Inc. grew its stake in shares of United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 28 shares during the period. Archer Investment Corp grew its stake in shares of United Therapeutics by 9.5% during the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 31 shares during the period. Finally, Signaturefd LLC grew its stake in shares of United Therapeutics by 4.1% during the 4th quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 35 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

UTHR stock opened at $556.82 on Friday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a market capitalization of $23.64 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 1.83 and a beta of 0.60. The business has a 50 day simple moving average of $566.51 and a two-hundred day simple moving average of $515.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.63 earnings per share. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 601,473 shares of company stock worth $337,090,644. 8.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on UTHR shares. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Royal Bank Of Canada cut their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.